PharmaShots | Incisive News in 3 Shots

Subscribe Now

EGFR Exon 20

Janssen's Rybrevant (amivantamab-vmjw) Receives the US FDA's Approval as the First Targeted Treatment for Patients with NSCLC with EGFR Exon 20 Insertion Mutations

Janssen's Rybrevant (amivantamab-vmjw) Receives the US FDA's Approval as the First Targeted Treatment for Patients with NSCLC with...

May 24, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us